Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur

The addition of pelabresib and ruxolitinib (Jakafi) led to a significant and durable reduction in splenomegaly, among other improvements, vs ruxolitinib alone in JAK inhibitor–naive patients with myelofibrosis.

Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations

Viktor Grünwald, MD, PhD, on patterns of progression and subsequent therapy for patients with advanced RCC treated during the phase 3 CLEAR trial.

Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Videos

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: 

The COMBI-AD dataset is the longest follow-up to date of adjuvant treatment for patients with stage III melanoma. 

Up to 10 Years of Follow-Up Uphold Survival Benefit With Adjuvant Dabrafenib/Trametinib in Stage III Melanoma 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement

AL Amyloidosis: Background, Patient Profile, and Staging

Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.

Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.

Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.

Navigating the Differential Diagnosis of AL Amyloidosis

Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.

Treatment Approaches in AL Amyloidosis 

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Limitations of Available Treatment Options for Patients with Cardiac Involvement 

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab Safety Profile in the VITAL Study

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Adverse Event Management in AL Amyloidosis

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Clinical Pearls and Future Directions in AL Amyloidosis

Insights Video Series

AL Amyloidosis: Background, Patient Profile, and Staging

EP: 1.AL Amyloidosis: Background, Patient Profile, and Staging

EP: 2.Navigating the Differential Diagnosis of AL Amyloidosis

EP: 3.Treatment Approaches in AL Amyloidosis

EP: 4.Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP: 5.Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP: 6.Birtamimab Safety Profile in the VITAL Study

EP: 7.Adverse Event Management in AL Amyloidosis

EP: 8.Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP: 9.Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP: 10.Clinical Pearls and Future Directions in AL Amyloidosis

Latest Conference Coverage